MOSCOW (MRC) -- Royal DSM N.V., a Life Sciences and Materials Sciences company, said its first-quarter EBITDA from continuing operations increased 19 percent to 296 million euros from 248 million euros in the prior year, as per Nasdaq.
Sales from continuing operations for the quarter were 1.913 billion euros, up 1 percent from last year's 1.886 billion euros in the year-ago period, due to 5 percent higher volumes, offset by 3 percent lower prices and 2 percent negative foreign exchange effects. Organic growth was 2 percent.
Looking ahead, DSM maintained its full-year outlook. The company aims to deliver increased full-year EBITDA and ROCE in line with the targets set out in its "Strategy 2018: Driving Profitable Growth".
We remind that, as MRC informed before, in May 2015, Royal DSM partnered with U.S. chemical maker Ascend Performance Materials Inc. to supply compounds based on polyamide 66 (PA66). Under the agreement, Houston, Tex.-based Ascend becomes the strategic supplier to DSM for PA66 base-polymer used as raw material for Akulon PA66 compounds for engineering plastics applications. In addition, DSM will distribute Ascend’s portfolio of PA66 compounds sold under the brand name Vydyne.
Royal DSM is a global science-based company active in health, nutrition and materials. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.
MRC